Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification by Fonio, Paolo et al.
1 3
Radiol med (2017) 122:713–721
DOI 10.1007/s11547-017-0770-6
VASCULAR AND INTERVENTIONAL RADIOLOGY
Incidence of hepatic encephalopathy after transjugular 
intrahepatic portosystemic shunt (TIPS) according to its severity 
and temporal grading classification
Paolo Fonio1 · Andrea Discalzi1 · Marco Calandri1 · Andrea Doriguzzi Breatta1 · 
Laura Bergamasco2 · Silvia Martini3 · Antonio Ottobrelli3 · Dorico Righi1 · 
Giovanni Gandini1 
Received: 3 March 2017 / Accepted: 19 April 2017 / Published online: 16 May 2017 
© Italian Society of Medical Radiology 2017
severity, whereas INR changes correlated with temporal 
frequency (p = 0.04). HE distribution classified for severity 
is similar at 6 and 12 months, whereas when classified for 
frequency shows significant differences (p = 0.04).
Conclusions A classification by gravity and frequency 
attests post-TIPS HE as a manageable risk. Monitoring of 
bilirubin and INR may help on clinical management risk 
stratification.
Keywords Radiology · Interventional · Portasystemic 
shunt · Transjugular intrahepatic · Hepatic encephalopathy · 
Liver · Liver cirrhosis
Abbreviations
TIPS  Transjugular intrahepatic portosystemic shunt
HE  Hepatic encephalopathy
INR  International normalized ratio
MELD  Model for end-of-stage liver disease
FU  Follow-up
ROC  Receiver-operating characteristic
AUC  Area under the curve
Abstract 
Objectives To evaluate hepatic encephalopathy (HE) inci-
dence after transjugular intrahepatic portosystemic shunt 
(TIPS) and classify by gravity and frequency.
Methods This is a retrospective study of 75 patients 
with no previous episodes of HE who underwent TIPS 
between 2008 and 2014 with clinical follow-up after 6 and 
12 months. Patient risk factors evaluated include age, INR 
(international normalized ratio), creatinine, bilirubin, and 
MELD score (Model for End-of-stage Liver Disease). HE 
was reported using two classifications: (1) gravity divided 
in moderate (West-Haven grades I–II) and severe (III–IV); 
(2) frequency divided in episodic and recurrent/persistent.
Results Overall HE incidence was 36% at 6 months, 
with 12 month incidence significantly decreased to 27% 
(p = 0.02). 13/75 (17%) patients had one episode of mod-
erate HE, while 3/75 (4%) patients had severe recurrent/
persistent HE. Age was the only pre-TIPS risk predic-
tor. Post-TIPS bilirubin and INR showed variations from 
basal values only in the presence of diagnosed HE. Biliru-
bin significantly increased (p = 0.03) in correlation to HE 
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Introduction
Transjugular intrahepatic portosystemic shunt (TIPS) 
proved to be an effective treatment for complications of 
portal hypertension, as rescue treatment when medical or 
endoscopic treatment fails in contrasting gastro-esopha-
geal variceal bleeding and as the first-line treatment for 
patients with refractory ascites, when frequent paracente-
sis is needed. [1–3].
The most common complication of TIPS is the devel-
opment of hepatic encephalopathy (HE), occurring in 
30–60% of patients within 1 year [2, 4–6]. The develop-
ment of HE represents an important drawback of this oth-
erwise valuable and life-prolonging intervention [2, 5, 7], 
being associated with significant morbidity and increased 
mortality [8, 9]. HE post-TIPS is typically attributed to 
the portosystemic shunt, but can be precipitated by abrupt 
changes in portal perfusion, shunt dysfunction, multiple 
hepatic re-interventions, and recurrent gastrointestinal 
bleeding or ascites [6]. Patients’ factors which might 
have an impact on the onset and features of HE are age, 
international normalized ratio (INR), serum creatinine, 
serum bilirubin, and the model for end-of-stage liver dis-
ease (MELD) score obtained from the latter three vari-
ables [7], which is an excellent predictor of survival in 
patients with end-stage liver disease.
The classification of HE as minimal, moderate, and 
severe was standardized in 1998 [10] and recently 
reviewed in 2014 in a more comprehensive classifica-
tion [11]. Despite this, in the radiological literature, there 
is heterogeneity of results regarding the incidence and 
impact of post-TIPS HE on clinical practice and quality 
of life. Some studies considered the overall episodes of 
HE, whereas others considered only the new or worsened 
HE episodes; some investigators selected the episodes 
that occurred without an evident precipitating cause [9], 
and others, those leading to hospitalization [5]; overt/cov-
ert differentiation was rarely used, while in most cases, 
moderate/severe classification is widely accepted [4]. 
Moreover, even if the diagnosis of severe HE is relatively 
straightforward on clinical grounds, it requires exclusion 
of other neuropsychiatric disorders that can be responsi-
ble for similar clinical findings. Particularly, the diagno-
sis of minimal HE requires formal neuropsychological 
assessment and testing. The reporting heterogeneity and 
the fact that only a few studies have a long-term follow-
up also affects the available meta-analyses [7].
An alternative HE classification based on the tempo-
ral occurrence and recurrence patterns of HE after TIPS 
was proposed in recent guidelines [11], but, as far as we 
know, it has not yet been used by radiologists.
The open questions are as follows:
1. Is it possible to identify pre-TIPS indicators (bio-
markers) of the middle (6 months) and long-term 
(1 year) post-TIPS outcome? For instance, how are 
the patient’s risk factors associated with the HE 
onset, features, and resolution?
2. What is the incidence of HE in its various forms at 6 
and 12 months?
3. Which extra information can be derived using both 
severity and time pattern classification?
Herein, we report and discuss the outcome of a retro-
spective evaluation of incidence, features, and evolution of 
HE in a cohort of cirrhotic patients treated with TIPS in our 
unit and followed for at least 1 year by the hepatology ref-
erence centre of our hospital. The goal of our study was to 
obtain a representation of the scenario at 6 and 12 months 
after the procedure based on both HE classifications (sever-
ity and temporal pattern grading).
Materials and methods
Study population
We retrospectively analyzed the radiological and clinical 
records of all consecutive cirrhotic patients who underwent 
a technically successful TIPS procedure in our unit from 
January 2008 to November 2014 and completed a 12 month 
follow-up (FU) period. The initial study sample included 
276 patients. Exclusion criteria were: lack of complete 
clinical information (112), liver transplantation during FU 
(43), death during FU (21), and pre-TIPS encephalopathy, 
since it might introduce a non-controllable bias (25). The 
final sample thus included 75/276 (27%) patients.
We chose to analyze the patients’ status as determined 
by our hepatology reference centre at 6 and 12 months as 
the best representative of the middle and long-term post-
TIPS evolution.
The study was conducted in good clinical practice 
according to the Helsinki Declaration of 1975 and subse-
quent modifications. Institutional review board approval 
was not required because of its retrospective nature. Writ-
ten informed consent was obtained from all patients before 
TIPS.
TIPS protocol
TIPS was performed according to conventional methods 
(Fig. 1) [2, 12]. Venous access was gained through the 
right jugular vein. A catheter was accessed into an hepatic 
vein, the right one for 56/75 patients (75%), and a Rosch–
Uchida transjugular liver access set (Cook Medical Co., 
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Bloomington, IN, USA) with ultrasound guide was used to 
penetrate the liver for access to the portal vein. The shunt 
was created with the right branch of the portal vein in 64 
patients (85%), with the left branch in 8 (11%) and in the 
bifurcation in 3 (4%). The stents were 11 Wallstent bare-
metal stents (Boston Scientific, Natick, MA, USA) (used 
from 2008 to 2010), 63 Viatorr covered-stent grafts (W. L. 
Gore & Associates, Flagstaff AZ, USA) (used from 2010 to 
2014), and 1 Luminexx (Bard, Tempe, AZ, USA) (used in 
2009).
To optimize the shunt, the stent was performed with a 
dilation balloon catheter of various sizes. In 71 patients, a 
single dilation was sufficient; when using the Viatorr stent, 
the dilation was performed with balloon catheters of maxi-
mum nominal diameter between 8 and 12 mm, while for 
patients with Luminexx or Wallstent stents, dilation ranged 
between 8 and 14 mm. Balloon dilation was followed by 
shunt venography.
In five cases (7%), the procedure was completed by 
embolization of the varicose periesophageal or perigas-
tric circles, highlighted on pre-procedural diagnostic 
angiography. After catheterization, the pressure before 
and after the balloon dilatation of the hepatic parenchy-
mal tract was evaluated.
Following TIPS procedures, patients underwent in-
patient monitoring for 48–72 h and were then followed 
as outpatients in the reference centre for liver failure and 
transplantation. Medication and diet of 75 patients after 
TIPS was the same—we recommended low-protein intake 
within 3 months after TIPS, especially the first month, and 
patients are always asked to keep good bowel movement. 
No patients were treated with anticoagulant therapy.
Fig. 1  TIPS procedure: a ultrasound-guided creation of shunt 
between the right hepatic vein and the right branch of the portal vein, 
b dilation of the parenchymal tract of the shunt, c Viatorr covered-
stent grafts deployment, d, e 8 mm balloon catheter is used to dilate 
the stent graft, and f final portography control
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HE classification
We followed the HE classification proposed in 2014 by the 
AASLD/EASL [11], adopting two different classifications:
1. Severity classification, the most used in radiological 
literature [4, 13, 14], divided into moderate (Grade I–
II West-Haven) and severe (Grade III–IV). We did not 
consider the minimal grade, for the uncertainties con-
nected with its diagnosis.
2. Time pattern classification, often used in gastroenter-
ology [11, 15–17], but generally neglected by radiolo-
gists, divided into episodic occurrence and recurrent 
(bouts of HE occurring within 6 months or less) or 
persistent (always present with intermittent episodes of 
overt HE) occurrence.
Statistical analysis
Continuous variables were tested for normality with the 
Shapiro–Wilks test. When normality was accepted (age), 
the data were presented as mean ± standard deviation; 
when normality was rejected (other risk factors), the data 
were presented as median and interquartile range (IQR). 
Comparisons employed non-parametric tests for k distribu-
tions— Mann–Whitney test for k = 2 and Kruskal–Wallis 
test for k > 2 independent distributions; Wilcoxon test for 
k = 2; and Friedman test for k > 2 correlated distributions.
The ability to differentiate between healthy and patho-
logical conditions was tested with the receiver operat-
ing characteristic (ROC) curve procedure; the quality of 
discrimination was quantified by the area under the curve 
(AUC), ranging from 0.5 (chance) to 1 (excellent). The 
threshold between the two conditions was set at the value 
which maximized Jouden’s index J and the harmonic mean 
(HM) of sensitivity (SNS) and specificity (SPC) while min-
imizing the distance D of the curve from the (0, 1) upper 
left vertex. SNS and SPC were used to determine the likeli-
hood ratio of a positive test LR+, i.e., the likelihood that a 
positive test result would be expected in a patient with dis-
ease compared to the likelihood that the same result would 
be expected in a patient without disease.
Categorical variables, reported as counts and percent-
ages, were arranged in r × c tables studied with the Chi-
square test (with Yates’ correction for 2 × 2 tables) or with 
Fisher’s exact test. McNemar’s test was used to assess the 
difference between two correlated proportions.
Statistical significance was set at two-tails p < 0.05.
The analysis was carried out with open source softwares 
(http://www.openepi.com and http://www.vassarstats.net) 
and Statplus:Mac version v6 (AnalystSoft, Walnut, USA). 
All statistical procedures were run on at least two different 
packages.
The statistical power of the study in some comparisons 
suffered from the low sample sizes, so some borderline 
values of p > 0.05 may actually hide significances that 
the test could not evidence; however, all results reported 
as significant originate from 80% power tests.
Results
HE incidence and risk factors
Table 1 shows the liver disease etiology and indication 
for TIPS for the 75 patients as assessed through the avail-
able clinical records.
At 6 months after TIPS, 27/75 (36%) patients were 
diagnosed with at least one episode of HE. Between 6 
and 12 months, 4 patients without HE at 6 months devel-
oped HE, while 11 patients with HE at 6 months recov-
ered— the rate of patients affected by HE at 12 months 
was thus down to 20/75 (27%), with a significant 11% 
difference (p = 0.02).
We checked whether the presence of at least one HE 
episode during the FU could be procedure-related, i.e., 
associated with values of the portal pressure gradient dur-
ing TIPS. All data are summarized in Table 2 and agree 
on the lack of significant differences between absence 
and presence of HE. The results were confirmed by the 
outcome of the logistic regression.
We considered the four patient-related risk fac-
tors— MELD score, INR, creatinine, and bilirubin, and 
the presence of a large volume of ascites on the day of 
TIPS procedure. We did not evaluate the presence of 
gastro-esophageal variceal for lack of information in the 
patients’ files and the albumin serum values for the high 
iatrogenic variations (for this last reason we did not cal-
culate retrospectively the Child-Pugh score).
Table 1  Liver disease etiology and indication for TIPS
Liver disease etiology
 Viral 34 (45%)
 Exotoxic 16 (21%)
 Cryptogenic 9 (12%)
 Others 16 (21%)
Indications for TIPS
 Refractory ascites 31 (41%)
 Acute gastro-esophageal variceal bleeding 7 (9%)
 Recurrent gastro-esophageal variceal bleeding 19 (25%)
 Massive portal vein thrombosis 12 (16%)
 Hepato-renal syndromes type II 4 (5%)
 Budd-Chiari syndrome 2 (3%)
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Table 3 compares the pre-TIPS values for the 31 
patients who at different times were diagnosed with HE 
and the 44 patients who did not have HE in the entire FU 
year. The only variable showing a significant difference 
between the two samples of patients is age. We tested its 
discrimination ability by studying the frequency distribu-
tions of the two samples and the associated ROC curve. 
The frequency distributions overlap over a substan-
tial region of age values (Fig. 2), crossing at 60 years. 
The ROC curve has AUC = 0.70, which stands for a 
moderate-to-fair discriminating ability; the ROC curve 
diagnostic parameters indicate age ≥60 years as thresh-
old for possible onset of HE (sensitivity = 71%, specific-
ity = 61.4%, likelihood Ratio-LR+ = 1.8).
To investigate the role of the other risk factors in deter-
mining the onset of HE, we studied their evolution in the 
follow-up period.
The 44 patients free from HE diagnosis over the entire 
1-year FU had similar values at pre-TIPS, 6-month and 
12-month tests for MELD (p = 0.47), INR (p = 0.49), 
creatinine (p = 0.38), and bilirubin (p = 0.17).
For the 31 patients who instead had HE either at 
6 months or at 12 months, we compared the pre-TIPS 
conditions to the conditions corresponding to the HE 
diagnosis (27 at 6 months and 4 at 12 months). The com-
parison clearly indicated that the onset of HE was asso-
ciated with a significant increase of bilirubin from the 
pre-TIPS value (p = 0.003). Such association was con-
firmed by the results relative to the 11 patients who at 
the 12-month check-up had recovered from the HE diag-
nosed at 6 months— recovery corresponded to a signifi-
cant (p = 0.03) decrease of bilirubin from HE to a value 
very close (p = 0.58) to the pre-TIPS one. Figure 3 illus-
trates the evolution of bilirubin over the three stages: pre-
TIPS, HE, and recovery. The values of INR and creati-
nine showed no significant variation.
Table 2  HE and portosystemic pressure gradient during TIPS procedure
Variable Patients without HE diagnosis Patients with HE diagnosis p
Caval pressure before TIPS (mmHg) 10.5 ± 6.3 11.6 ± 3.6 0.41
Portal pressure before TIPS (mmHg) 33.7 ± 8.1 36.5 ± 6.7 0.14
Portal pressure gradient before TIPS (mmHg) 24.1 ± 6.1 24.1 ± 6.7 >0.99
Caval pressure after TIPS (mmHg) 18.0 ± 6.3 19.4 ± 5.0 0.32
Portal pressure after TIPS (mmHg) 25.7 ± 7.0 27.0 ± 5.2 0.44
Portal pressure gradient after TIPS (mmHg) 8.4 ± 2.6 7.9 ± 2.3 0.46
Difference in portal pressure gradient before and after TIPS (mmHg) 15.8 ± 5.3 15.8 ± 5.9 0.98
Table 3  pre-TIPS conditions 
and HE post-TIPS
a
 Model for end-stage liver disease
b
 International normalized ratio
c
 Large abscites on the day of TIPS procedure
Patients without HE diagnosis Patients with HE diagnosis p
Patients 44 31
Males 30 (61%) 19 (68%) 0.71
Age (years) 52.9 ± 9.4 59.1 ± 9.5 0.01
MELDa score 12 (9.7–15) 12 (11–16) 0.31
INRb 1.3 (1.2–1.5) 1.4 (1.2–1.5) 0.23
Creatinine (mg/dL) 0.88 (0.71–1.0) 0.95 (0.84–1.2) 0.09
Bilirubin (mg/dL) 1.65 (1–2.35) 1.5 (1.2–1.95) 0.51
Abscitesc 31 23 0.73
Fig. 2  Age and frequency distributions on the two samples
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HE classification
The 31 patients who suffered from HE had a total of 
47 HE diagnoses (27 at the 6-month check-up and 20 
at the 12-month check-up). Table 4 shows how they fit 
the two classifications—in horizontal, the severity grad-
ing; in vertical, the time recurrence pattern; and in bold, 
the two conditions that combine a high level of sever-
ity with a high frequency of recurrence, i.e., the worst 
to manage and those seriously damaging the qual-
ity of life of the patients. One patient was affected by 
severe recurrent/persistent HE both at the 6-month and 
12-month check-ups.
Severity grading and temporal pattern grading
At 6 months, there were 23 patients with moderate HE and 
four with severe HE, whereas at 12 months, there were 18 
moderate HE and two severe HE, with a similar distribution 
between moderate and severe (p = 0.46). The main features 
of the 47 HEs observed at 6 and 12 months (41 moderate 
and six severe) are reported in Table 5 (left side).
At 6 months, there were 13 patients with episodic HE 
and 14 with recurrent/persistent HE; at 12 months, there 
were three episodic HEs and 17 recurrent/persistent HEs. 
Interestingly, the distribution according to the temporal 
pattern was significantly different at the two check-ups, 
with the episodic HEs decreasing and the more fastidi-
ous recurrent/persistent ones increasing (p = 0.04). Seven 
patients with Episodic HE at 6 months recovered, three 
remained stable and four worsened to recurrent/persistent; 
at the same time, one patient with recurrent/persistent HE 
improved to episodic. The main features of the 47 HEs 
observed at the two checkpoints of 6 and 12 months (over-
all 16 Episodic, 31 Recurrent/Persistent) are reported in 
Table 5 (right side).
Fig. 3  Evolution of bilirubin over the three stages— pre-TIPS, HE, 
and recovery
Table 4  Details of the 47 diagnosed HEs
6 months HE 27/75 (36%)
Moderate Severe
Episodic 11 2 13 (17%)
Recurrent/persistent 12 2 14 (19%)
23 (31%) 4 (5%)
12 months HE 20/75 (27%)
Moderate Severe
Episodic 2 1 3 (4%)
Recurrent/persistent 16 1 17 (22%)
18 (24%) 2 (3%)
Pooled 41 6 47
Table 5  Details of the 47 diagnosed HEs using the severity grading (left side) and the temporal pattern grading (right side)
Bold values indicate statistical significance P values (p < 0.05)
Variable HE
Moderate HE (n = 41) Severe HE (n = 6) p Episodic (n = 16) Recurrent/persistent (n = 31) p
Age 58.8 ± 9.6 63.3 ± 9.1 0.25 60.2 ± 9.3 59.2 ± 8.7 0.65
MELD 13 (11–15) 18 (13–20) 0.11 14 (1.7–15) 13 (12–16) 0.73
INR 1.44 (1.27–1.59) 1.36 (1.3–1.4) 0.70 1.29 (1.18-1.48) 1.46 (1.4–1.6) 0.04
Creatinine (mg/dL) 0.88 (0.78–0.99) 1.12 (1.0–1.5) 0.09 0.87 (0.82–1.01) 0.90 (0.78–1.03) 0.77
Bilirubin (mg/dL) 1.7 (1.1–2.5) 3.7 (2.1–4.7) 0.03 2.4 (1.7–3.5) 1.65 (0.95–2.5) 0.10
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Discussion
The results of our study sketch a picture of the onset 
and evolution of HE at 6 and 12 months after the TIPS 
procedure from two different points of view— sever-
ity grading—the most generally used—and temporal 
pattern grading—recently emphasized by the AASLD-
EASL, but until now, scarcely adopted in the radiological 
environment.
The main results of our study are—
–– the overall HE incidence significantly decreased from 
27/75 (36%) at 6 months to 20/75 (27%) at 12 months, 
(p = 0.02). 44/75 (59%) patients enjoyed complete 
freedom from HE, and 13/75 (17%) had only one epi-
sode of moderate HE— overall, the procedure may be 
considered safe for 57/75 (76%) patients. The proce-
dure was cause of heavy distress (severe recurrent/
persistent HE) only for 3/75 (4%) patients;
–– among all pre-TIPS risk factors, age ≥60 years was 
identified as a fair indicator of increased probability 
of post-TIPS HE;
–– the onset of HE was associated with a significant 
increase in the bilirubin value (p = 0.003), just as 
recovery from HE was associated with a significant 
decrease to the basal value. In addition, the increas-
ing severity of HEs was significantly associated with 
increasing values of bilirubin (p = 0.03), whereas 
the increasing frequency of HEs was associated with 
increasing values of INR (p = 0.04);
–– the HE distribution, classified according to severity, 
was similar at 6 and 12 months (p = 0.46), whereas 
when classified according to the temporal pattern 
grading, it showed significant differences (p = 0.04), 
due to the decrease of episodic HEs and increase of 
persistent HEs.
Comprehensive incidence of HE
The overall incidence of patients with HE at 6 months 
(36%) of our series is at the bottom of the range of val-
ues present in the literature (from 30 to 60%). [7, 18, 19] 
Considering both severity and temporal pattern grading, 
we obtain that a large percentage of patients (76%) had 
no HE or had a single moderate episode that was easily 
managed. The worst condition, a severe recurrent/per-
sistent HE, was, indeed, a rare situation (4%). The risks 
associated with post-TIPS morbidity are not negligible, 
but they must be balanced against its potential benefits, 
being aware that untreatable variceal hemorrhage and 
refractory ascites have in 30–50% of cases a survival 
time of about 2 years [20, 21].
Predictive factors
In our series, age was the only pre-TIPS variable signifi-
cantly associated with HE onset (p = 0.01), with patients 
above 60 years, the most probable candidates. The likeli-
hood ratio for a positive test is 1.8, increasing to 4.2 for 
ages ≥70 years. This is consistent with the results by Bai 
[7], who demonstrated that older patients were usually 
accompanied by a higher post-TIPS HE risk and those by 
Hassoun [22], who hypothesized that the aging brain may 
be more susceptible to the toxic effects of substances such 
as ammonia involved in pathogenesis of HE.
Bilirubin associated with HE onset and severity grading
We assessed a significant increase of bilirubin from the 
pre-TIPS value (p = 0.003) to the onset of HE, with val-
ues higher for severe than for moderate HEs (p = 0.03). 
Accordingly, the recovery corresponded to a significant 
decrease of bilirubin to basal values (p = 0.58).
The increase in serum bilirubin is a well-known direct 
indicator of hepatocyte dysfunction, especially in the days 
following the shunt creation. Casadaban [23] described an 
acute (within 7 days) two- to three-fold increase in biliru-
bin, typically resolved within 2 weeks, remaining far from 
the baseline value only for patients with 90-day mortality. 
The transient nature of these alterations is explained by 
the sudden decrease of hepatic flow; the subsequent arte-
rial perfusion compensation (“the hepatic arterial buffer 
response” [24, 25]) may allow relative normalization of 
laboratory test results after TIPS. Although the authors 
do not describe any correlation between hepatobiliary 
enzymatic elevation and HE, we can assert that the more 
compromised is the liver function (e.g., longer is bilirubin 
elevation), the higher is the risk of HE. It is the precisely 
timed association: HE presence—high bilirubin versus HE 
absence—basal bilirubin that prevents bilirubin to be used 
as pre-TIPS predictor.
INR associated with HE temporal pattern grading
In contrast to bilirubin, the value of INR was not sig-
nificantly associated with HE onset and severity grading; 
however, when considering the data in the temporal pat-
tern frame, we evidenced a significant association between 
increasing frequency of HE episodes and increasing values 
of INR (p = 0.04).
This difference in behavior according to the classifica-
tion method is intriguing. INR is a marker of liver func-
tion which is known to usually increase in the latest 
stages [26, 27] of liver disease, when presumably patients 
may suffer from more frequent HE episodes. Indeed, 
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Pomier-Layrargues [26] described that the first sign of liver 
failure is a progressive increase in the serum bilirubin, fol-
lowed by a rise in INR, onset of encephalopathy, and death 
due to multiorgan failure.
HE incidence at 6 and 12 months
The 12-month FU witnessed a significant 11% decrease 
(p = 0.016) in the number of patients affected by HE 
compared to the 6-month FU. When considering the 
severity grading, the distribution between moderate 
and severe was essentially similar (p = 0.46) at the two 
checkpoints. Instead of considering the temporal crite-
ria, we recognized a significant change (p = 0.04) in the 
ratio of episodic to recurrent/persistent occurrences—
at 6 months, there was a prevalence of episodic HEs, 
whereas at 1 year, the ratio was turned over with preva-
lence of recurrent/persistent occurrences. The preva-
lence of episodic HEs at 6 months is most probably due 
to the temporary changes caused by TIPS, possibly due 
to the suddenly increased shunt flow. More difficult to 
explain is the reason underlying the long-term evolution 
from episodic to the more devastating recurrent/persis-
tent form, also because of the small number of patients 
involved (n=4).
Limitations
This study has several limitations: (1) data were collected 
retrospectively and, hence, non-randomized; (2) patient 
treatment spanned over 7 years, with consequent dif-
ferences in their treatment; (3) development of HE was 
determined subjectively by the hepatologists and knowl-
edge about HE features were limited to information avail-
able in patient files. We did not evaluate HE incidence 
according to the stent type for the high predominance of 
PTFE-covered stent used. We could not evaluate 3-month 
(short-term) HEs according to the existence of precipitat-
ing factors nor use the overt/covert classification for lack 
of information in the patient’s files.
Conclusions
Our study determines an overall HE incidence of 36% at 
6 months, decreasing to 27% at the 1-year FU. The com-
prehensive (severity and temporal) classification of HE 
evidenced that the more devastating form of severe recur-
rent/persistent HE struck only 4% of the patients.
Age can be considered as pre-TIPS risk predictor, 
advising a careful evaluation of patients over 60 years for 
their significantly higher probability of HE. Furthermore, 
bilirubin is closely associated with the level of severity 
characterizing the HE, whereas INR is associated with 
the temporal occurrence of HE.
Although our study involves one of the biggest single 
institution series [7], a reliable test of the validity of the 
“cross-classification” matching severity and frequency will 
require a specifically designed prospective study, possibly 
a well-coordinated multicenter study to collect large num-
bers in a short period of time, guaranteeing the necessary 
homogeneity of treatment. In conclusion, our study under-
lines the need for a standardization of the reporting criteria 
of post-TIPS HE to better compare data within the radio-
logical community and interact with other specialists.
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